Innovating Works

SICTEC

Financiado
Single Cell Technologies for SMEs
This project is focused on development of technologies for separation and manipulation of single biological cells for life science research and medical applications. The research plan is built upon the results of the FP7 project P... This project is focused on development of technologies for separation and manipulation of single biological cells for life science research and medical applications. The research plan is built upon the results of the FP7 project PASCA (GA 257073, started 01.09.2010). The single cell manipulation technology (SCM technology) developed there is based on inkjet-like printing of single biological cells confined in free flying micro droplets. It constitutes a universal platform for single cell analysis that has been proven to have high potential for many life science applications. The objective of this project is to support the participating SMEs and companies to take up the SCM technology, to realize their own applications and to develop them into innovative products for the medical, biomedical and pharmaceutical markets. Central element of the research is the SCM prototype instrument as presented in numerous publications (see www.pasca.eu). The actual project will provide validation and extension of the use of this prototype instrument and deal with necessary improvements and modifications of pre-production prototypes towards the specific needs and applications of the SME partners. In particular also topics affecting commercial exploitation like e.g. application development, design for manufacturability, reliability issues, cost and throughput optimization, extension of technical specifications, and preparation of CE IVD labeling will be investigated. Applications targeted by the individual SMEs are considering fast pathogen detection for clinical use by combining the SCM technology with MALDI TOF mass spectroscopy of single bacteria, instruments for single cell cancer and stem cell research, methods for monoclonal cell line development and in-vitro medical diagnostic applications. The anticipated innovations stemming from this research will be exploited by the involved SMEs individually as well as jointly through several innovative products targeted for different markets and applications. ver más
30/09/2015
BIOFLUIDIX GMBH
1M€

Línea de financiación: concedida

El organismo FP7 notifico la concesión del proyecto el día 2015-09-30
Presupuesto El presupuesto total del proyecto asciende a 1M€
Líder del proyecto
BIOFLUIDIX GMBH No se ha especificado una descripción o un objeto social para esta compañía.